We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Gut check

8 November 2016 By Kevin Allison

The $80 bln drugstore chain warned that profit growth would slow down. Fewer customers and the loss of a couple big contracts were factors. Industry-wide pricing pressure adds to the challenge. Two big deals last year worth a combined $14 bln may be causing bad side effects.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)